Thelansis

  Myofascial Pain Syndrome (MPS) Market Outlook Thelansis’s “Myofascial Pain Syndrome (MPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myofascial Pain Syndrome (MPS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Myofascial Pain Syndrome (MPS) Overview Myofascial pain syndrome (MPS) is prevalent among individuals experiencing musculoskeletal discomfort. It manifests as localized or referred pain stemming from the muscle and the surrounding fascia. Contributing factors to MPS include traumatic events, ergonomic issues, structural anomalies, and systemic conditions. Currently, the precise pathophysiology of MPS remains elus...

  Myofascial pain syndrome (MPS) is prevalent among individuals experiencing musculoskeletal discomfort. It manifests as localized or referred pain stemming from muscle and the surrounding fascia. Contributing factors to MPS include traumatic events, ergonomic issues, structural anomalies, and systemic conditions. Currently, the precise pathophysiology of MPS remains elusive. Among these, one of the most widely accepted theories revolves around the energy crisis within muscle fibers. Diagnosis relies on clinical assessments, although medical tools such as electromyography and ultrasound can confirm it. Electromyography typically detects end-plate noise in trigger points (TrPs), while ultrasound can differentiate TrPs by revealing hypoechoic areas compared to surrounding muscles. Treatment aims at alleviating pain and addressing underlying causes. Education on stretching exercises and ergonomic adjustments is essential for all patients. Although nonsteroidal anti-inflammatory drug...